Castle Biosciences Inc., a company focused on improving health through innovative tests, announced the approval of new compensation terms involving restricted stock units (RSUs) for 66 employees. On June 14, 2025, the Compensation Committee of the Board of Directors granted RSUs covering a total of 135,978 shares of common stock as part of the company's 2022 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a period of four years, with 25% vesting on the first anniversary of the vesting commencement date, and the remaining shares vesting in three equal annual installments, contingent on continued employment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。